TICKERNERD
Menu
AGLAGLHealthcare · Medical Care Facilities

AGL Stock Forecast: Agilon Health, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$87
+1.75% on the day

The 15 Wall Street analysts covering Agilon Health, Inc. hold a median 12-month price target of $115 — +31.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
70 / 100
Median analyst target
$115
Analysts covering
15
Revenue$1.5B+7.2% y/y
Operating income$11.8M
Net income$18.0M
Free cash flow−$61.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.0%
1M
−5.4%
YTD
+407.4%
1Y
+282.5%
From 52W high
−32.7%
From 52W low
+1004.9%
$8
$130
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Agilon Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Growth
85
Momentum
84
Revisions
75
Issuance
69
Value
40
Size
39
Quality
16
Volatility
6

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (6): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Jan 26Apr 26Jul 26Oct 26AGLHigh $146Median $115Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
5 Buy9 Hold1 Sell
Low $85Median $115High $146

The green dot is the last close — the median target sits +31.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
15 Sept 2026BernsteinUpgradeOutperform$86 → $125
24 Aug 2026JP MorganMaintainsUnderweight—
24 Aug 2026JP MorganMaintainsUnderweight$31 → $85
11 Aug 2026CitigroupUpgradeNeutral—
11 Aug 2026CitigroupUpgradeNeutral$105 → $115
11 Aug 2026Wells FargoMaintainsOverweight$141 → $146
11 Aug 2026Wells FargoMaintainsOverweight—
6 Aug 2026BarclaysMaintainsEqual-Weight$81 → $111
6 Aug 2026BarclaysMaintainsEqual-Weight—
6 Aug 2026BenchmarkMaintainsBuy—
6 Aug 2026BenchmarkMaintainsBuy$95 → $140
6 Aug 2026Evercore ISI GroupMaintainsIn-Line$120 → $125
6 Aug 2026Evercore ISI GroupMaintainsIn-Line—
6 Aug 2026Truist SecuritiesMaintainsHold—
6 Aug 2026Truist SecuritiesMaintainsHold$67 → $112
23 July 2026CitigroupDowngradeSell—
23 July 2026CitigroupDowngradeSell$80 → $105
13 July 2026Wells FargoMaintainsOverweight$72 → $141
13 July 2026Wells FargoMaintainsOverweight—
26 May 2026BarclaysUpgradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Agilon Health, Inc. returned +282.5% against +17.5% for the S&P 500, dividends included.

AGL vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400500600Jan 26Apr 26Jul 26Oct 26AGLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Agilon Health, Inc. (AGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.6×

Cheaper than 89% of US stocks

Price / sales
0.2×

Cheaper than 90% of US stocks

Price / book
6.3×

Cheaper than 15% of US stocks

EV / EBITDA
−5.4×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
7.2%

Higher than 45% of US stocks

Earnings growth (YoY)
7.2%

Higher than 44% of US stocks

Gross margin
7.2%

Higher than 7% of US stocks

Operating margin
1.3%

Higher than 47% of US stocks

Net margin
−3.9%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−78.9%

Higher than 16% of US stocks

Return on assets
−9.6%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Agilon Health, Inc. (AGL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Agilon Health, Inc. has a market value of $1.4B and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $5.9B. The latest quarter grew 7.2% year on year.

  • Net income over the same four quarters: −$232.2M, a −3.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−14.27.

  • Free cash flow in the twelve months to 30 June 2026: −$106.0M.

  • Shares outstanding: 16.8M.

  • Trailing P/E: −3.6×; forward P/E: 36.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Agilon Health, Inc. employs 856 people — $6.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

AGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
AGLAgilon Health, Inc.$1.4B
70
AMNAMN Healthcare Services, Inc.$1.5B
100
PNTGThe Pennant Group, Inc.$1.4B
72
HCSGHealthcare Services Group, Inc.$1.5B
95
NUTXNutex Health, Inc.$1.4B
88
USPHU.S. Physical Therapy, Inc.$1.3B
57
SNDASonida Senior Living, Inc.$1.7B
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Agilon Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AGL news & analysis

Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 7 Oct 2026neutral

Zacks Investment Research compares Agilon Health (AGL) and CRISPR Therapeutics (CRSP) with their sector based on performance so far this year. The excerpt does not provide performance results or say whether AGL is outpacing its peers.

Why it matters — AGL watchers may find the year-to-date peer comparison relevant, but the excerpt offers no results to assess AGL’s relative performance.

agilon health Sets Date to Report Third Quarter 2026 Financial Results

Business Wire · 5 Oct 2026neutral

agilon health announced it will release its third quarter 2026 financial results after market close on Wednesday, November 4, 2026, and will host a conference call at 4:30 p.m. ET to discuss the results. Dial-in details were provided for U.S. and international participants.

Why it matters — Investors and analysts following AGL will mark this date on the calendar to hear the company's latest quarterly financial results and management commentary.

agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO

Business Wire · 30 Sept 2026positive

agilon health announced an expansion of its partnership with The Jackson Clinic, one of Tennessee's largest independent physician organizations with over 130 providers across 13 locations, which will join one of agilon's Senior Health Connect Accountable Care Organizations.

Why it matters — This expansion grows agilon's physician network and ACO participation, potentially strengthening its value-based care platform and market presence in Tennessee.

agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO

Business Wire · 23 Sept 2026positive

agilon health announced an expanded partnership with Springfield Clinic in Illinois, which will join one of agilon's Senior Health Connect Accountable Care Organizations. Springfield Clinic is a community-based practice with more than 650 physicians and advanced practitioners serving over 80 sites.

Why it matters — This expansion broadens agilon's physician network and ACO participation, potentially supporting growth in its value-based care model.

This Ulta Beauty Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Benzinga · 15 Sept 2026neutral

Benzinga reported on the top five analyst rating upgrades for Tuesday, including one analyst who is no longer bearish on Ulta Beauty. The article directs readers to its analyst ratings page for a complete view of all rating changes, including upgrades, downgrades, and initiations.

Why it matters — AGL watchers may find the article relevant as a general indicator of analyst sentiment shifts in the market, though it contains no specific mention of Agilon Health.

FAQ

Frequently asked questions about AGL stock

What is the AGL stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Agilon Health, Inc. have a median 12-month price target of $115, with estimates ranging from $85 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGL stock a buy right now?

Of the 15 analysts covering Agilon Health, Inc., 5 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Agilon Health, Inc. 70 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGL?

As at 14 Oct 2026, Agilon Health, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will AGL stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +31.6% from the last close, and Ticker Nerd's factor model ranks Agilon Health, Inc. 70 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGL stock forecast for 2030?

No analyst covering Agilon Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $146 over the next 12 months.

How has AGL stock performed over the past year?

Agilon Health, Inc. returned +282.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agilon Health, Inc. do?

agilon health, Inc. is a healthcare services company focused on supporting primary care physicians in managing senior patients through value-based care arrangements.

What is the latest news on AGL?

The most recent item we track (Zacks Investment Research, 7 Oct 2026): "Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?". Zacks Investment Research compares Agilon Health (AGL) and CRISPR Therapeutics (CRSP) with their sector based on performance so far this year. The excerpt does not provide performance results or say whether AGL is outpacing its peers.

Company

About Agilon Health, Inc.

agilon health, Inc. is a healthcare services company focused on supporting primary care physicians in managing senior patients through value-based care arrangements. The company provides a platform that helps physician groups coordinate care, manage total patient health needs, and operate under capitated reimbursement models designed around Medicare beneficiaries. Its services include care coordination, payer contracting support, population health analytics, quality management, and operational infrastructure for community-based physician practices. agilon health works primarily with independent primary care groups across the United States, helping them deliver integrated care in local markets while shifting administrative and clinical support tasks to its platform. The company plays a role in the broader healthcare market by enabling physician-led models that emphasize coordinated treatment, preventive care, and management of chronic conditions for older adults.

CEO Mr. Timothy Patrick O'Rourke · 856 employees · United States · https://www.agilonhealth.com